Radiation and Cancer Biology
Mukesh Nyati, PhD
Associate Professor of Radiation Oncology
Professor Nyati received his Ph.D. from the University of Rajasthan, Jaipur, India and post-doctoral training in Dr. Ted Lawrence’s laboratory at the University of Michigan. Dr. Nyati has been working on basic, translational as well as clinical aspect of EGFR signaling. His research is continued to be funded by NIH. In the laboratory, Dr. Nyati is working on developing novel therapeutic agents including cell permeable peptides and their structural analogues to degrade EGFR. The main objective of this work is to sensitize tyrosine kinase inhibitor (TKI) resistant EGFR-driven tumors by promoting tumor specific EGFR degradation through blocking EGFR dimers and EGFR Hsp90 interactions. Dr. Nyati is also working in collaboration with both basic scientist and clinicians in the head and neck SPORE program at the University of Michigan to discover novel biomarkers of “response” to molecularly targeted therapy. The long- term goal of this research is to identify patients who are likely to respond to molecularly targeted therapy in combination with chemotherapy and/or radiotherapy early in the course of treatment so that the combination regimen is optimized.
Faculty Appointment: Associate Professor, Department of Radiation Oncology
Specialty: Radiation Oncology
Research Interests: Signal transduction, protein degradation, radiation sensitization and experimental therapeutics.
Degree: Ph.D., 1996, University of Rajasthan, Jaipur, INDIA
Added Qualification: 1997, Ph.D.
Faculty Appointment: Date:1/7/1999
Contact: email@example.com or firstname.lastname@example.org
Drs. Nyati and Lawrence
|Back to top|